Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D

Clinical and Vaccine Immunology

Volumn 15, Issue 9, 2008, Pages 1436-1449

  Zhang, Xiuli ^a   Castelli, Florence A ^b   Zhu, Xiaoming ^a   Wu, Michele ^a   Maillère, Bernard ^b   BenMohamed, Lbachir ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR13 ANTIGEN; HLA DR15 ANTIGEN; HLA DR4 ANTIGEN; HLA DR7 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENDER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ADOLESCENT; ADULT; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HERPESVIRUS 1, HUMAN; HERPESVIRUS VACCINES; HLA-DR ANTIGENS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; SEX; VIRAL ENVELOPE PROTEINS;

EID: 51649112932     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00123-08     Document Type: Article

References (86)

1. BenMohamed, L., Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32:2274-2281.
2. + Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77:9463-9473.
3. BenMohamed, L., H. Gras-Masse, A. Tartar, P. Daubersies, K. Brahimi, M. Bossus, A. Thomas, and P. Druilhe. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242-1253.
4. BenMohamed, L., R. Krishnan, C. Auge, J. F. Primus, and D. J. Diamond. 2002. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106:113-121.
5. H response. Hum. Immunol. 61:764-779.
6. BenMohamed, L., A. Thomas, M. Bossus, K. Brahimi, J. Wubben, H. Gras-Masse, and P. Druilhe. 2000. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum preerythrocytic molecules. Vaccine 18:2843-2855.
7. BenMohamed, L., S. L. Wechsler, and A. B. Nesburn. 2002. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2:425-431.
8. Bernstein, D. 2005. Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Rev. Vaccines 4:615-627.
9. Bertoni, R., J. Sidney, P. Fowler, R. W. Chesnut, F. V. Chisari, and A. Sette. 1997. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J. Clin. Investig. 100:503-513.
10. + T cell epitopes. Cancer Immunol. Immunother. [Epub ahead of print.] doi:10.1007/s00262-008-0537-y.
11. Bettahi, I., A. B. Nesburn, S. Yoon, X. Zhang, A. Mohebbi, V. Sue, A. Vanderberg, S. L. Wechsler, and L. BenMohamed. 2007. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Investig. Ophthalmol. Vis. Sci. 48:4643-4653.
12. Bettahi, I., X. Zhang, R. E. Afifi, and L. BenMohamed. 2006. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 19:220-236.
13. Blaney, J. E., Jr., E. Nobusawa, M. A. Brehm, R. H. Bonneau, L. M. Mylin, T. M. Fu, Y. Kawaoka, and S. S. Tevethia. 1998. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 72:9567-9574.
14. Bossus, M., L. Benmohamed, A. Londono, B. Barbier, A. Tartar, P. Druilhe, and H. Gras-Masse. 1997. Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues. J. Pept. Sci. 3:47-53.
15. Bourne, N., F. J. Bravo, M. Francotte, D. I. Bernstein, M. G. Myers, M. Slaoui, and L. R. Stanberry. 2003. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis. 187:542-549.
16. Brahimi, K., E. Badell, J.-P. Sauzet, L. BenMohamed, P. Daubersies, C. Guérin-Marchand, G. Snounou, and P. Druilhe. 2001. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infect. Immun. 69:3845-3852.
17. + T cells. J. Immunol. 178:778-787.
18. + cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180:426-437.
19. + T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038-1044.
20. + CTL epitope located at the transmembrane-cytoplasmic junction. Cell. Immunol. 239:113-120.
21. Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A. A. Adimora, P. Leone, C. L. Dekker, R. L. Burke, W. P. Leong, and S. E. Straus. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282:331-340.
22. Cornberg, M., A. T. Chen, L. A. Wilkinson, M. A. Brehm, S. K. Kim, C. Calcagno, D. Ghersi, R. Puzone, F. Celada, R. M. Welsh, and L. K. Selin. 2006. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J. Clin. Investig. 116:1443-1456.
23. Cunningham, A. L., R. J. Diefenbach, M. Miranda-Saksena, L. Bosnjak, M. Kim, C. Jones, and M. W. Douglas. 2006. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 194(Suppl. 1):S11-S18.
24. Damhof, R. A., J. W. Drijfhout, A. J. Scheffer, J. B. Wilterdink, G. W. Welling, and S. Welling-Wester. 1993. T cell responses to synthetic peptides of herpes simplex virus type 1 glycoprotein D in naturally infected individuals. Arch. Virol. 130:187-193.
25. Dana, M. R., Y. Qian, and P. Hamrah. 2000. Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 19:625-643.
26. Danve-Szatanek, C., M. Aymard, D. Thouvenot, F. Morfin, G. Agius, I. Bertin, S. Billaudel, B. Chanzy, M. Coste-Burel, L. Finkielsztejn, H. Fleury, T. Hadou, C. Henquell, H. Lafeuille, M. E. Lafon, A. Le Faou, M. C. Legrand, L. Maille, C. Mengelle, P. Morand, F. Morinet, E. Nicand, S. Omar, B. Picard, B. Pozzetto, J. Puel, D. Raoult, C. Scieux, M. Segondy, J. M. Seigneurin, R. Teyssou, and C. Zandotti. 2004. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J. Clin. Microbiol. 42:242-249.
27. Daubersies, P., A. W. Thomas, P. Millet, K. Brahimi, J. A. Langermans, B. Ollomo, L. BenMohamed, B. Slierendregt, W. Eling, A. Van Belkum, G. Dubreuil, J. F. Meis, C. Guerin-Marchand, S. Cayphas, J. Cohen, H. Gras-Masse, and P. Druilhe. 2000. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med. 6:1258-1263.
28. DeFreitas, E. C., B. Dietzschold, and H. Koprowski. 1985. Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D. Proc. Natl. Acad. Sci. USA 82:3425-3429.
29. Fidock, D. A., H. Gras-Masse, J. P. Lepers, K. Brahimi, L. BenMohamed, S. Mellouk, C. Guerin-Marchand, A. Londono, L. Raharimalala, J. F. Meis, et al. 1994. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J. Immunol. 153:190-204.
30. Field, P. R., D. W. Ho, W. L. Irving, D. Isaacs, and A. L. Cunningham. 1993. The reliability of serological tests for the diagnosis of genital herpes: a critique. Pathology 25:175-179.
31. + T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retrovir. 22:684-694.
32. + T cells in humans after lipopeptide vaccination. AIDS Res. Hum. Retrovir. 23:427-437.
33. Ghiasi, H., R. Kaiwar, A. B. Nesburn, S. Slanina, and S. L. Wechsler. 1994. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J. Virol. 68:2118-2126.
34. Grammer, S. F., A. Sette, S. Colon, L. Walker, and R. Chesnut. 1990. Identification of an HSV-1/HSV-2 cross-reactive T cell determinant. J. Immunol. 145:2249-2253.
35. Han, X., P. Lundberg, B. Tanamachi, H. Openshaw, J. Longmate, and E. Cantin. 2001. Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J. Virol. 75:3048-3052.
36. Heber-Katz, E., S. Valentine, B. Dietzschold, and C. Burns-Purzycki. 1988. Overlapping T cell antigenic sites on a synthetic peptide fragment from herpes simplex virus glycoprotein D, the degenerate MHC restriction elicited, and functional evidence for antigen-Ia interaction. J. Exp. Med. 167:275-287.
37. Klein, N. P., T. H. Holmes, M. A. Sharp, T. C. Heineman, M. R. Schleiss, D. I. Bernstein, G. Kemble, A. M. Arvin, and C. L. Dekker. 2006. Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine 24:5913-5918.
38. Koelle, D. M. 2006. Vaccines for herpes simplex virus infections. Curr. Opin. Investig. Drugs 7:136-141.
39. Koelle, D. M., and L. Corey. 2008. Herpes simplex: insights on pathogenesis and possible vaccines. Annu. Rev. Med. 59:381-395.
40. + T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 68:2803-2810.
41. Koelle, D. M., J. M. Frank, M. L. Johnson, and W. W. Kwok. 1998. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J. Virol. 72:7476-7483.
42. Kovats, S., and E. Carreras. 13 February 2008. Regulation of dendritic cell differentiation and function by estrogen receptor ligands. Cell. Immunol. [Epub ahead of print.] doi:10.1016/j.cellimm.2007.10.008.
43. Kruszon-Moran, D., and G. M. McQuillan. 2005. Seroprevalence of six infectious diseases among adults in the United States by race/ethnicity: data from the third national health and nutrition examination survey. 1988-94. Adv. Data 352:1-9.
44. Lapkus, O., T. M. Elsheikh, B. A. Ujevich, Y. L. Liu, and J. F. Silverman. 2006. Pitfalls in the diagnosis of herpes simplex infection in respiratory cytology. Acta Cytol. 50:617-620.
45. Lee, H. S., Y. H. Chung, T. G. Kim, T. H. Kim, J. B. Jun, S. Jung, S. C. Bae, and D. H. Yoo. 2003. Independent association of HLA-DR and FCγ receptor polymorphisms in Korean patients with systemic lupus erythematosus. Rheumatology (Oxford) 42:1501-1507.
46. Mbopi-Kéou, F. X., G. Gresenguet, P. Mayaud, H. A. Weiss, R. Gopal, M. Matta, J. L. Paul, D. W. Brown, R. J. Hayes, D. C. Mabey, and L. Belec. 2000. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J. Infect. Dis. 182:1090-1096.
47. McQuillan, G. M., D. Kruszon-Moran, B. J. Kottiri, L. A. Kamimoto, L. Lam, M. F. Cowart, M. Hubbard, and T. J. Spira. 2006. Prevalence of HIV in the US household population: the National Health and Nutrition Examination Surveys, 1988 to 2002. J. Acquir. Immune Defic. Syndr. 41:651-656.
48. MeŸó, G., Z. Majer, E. Vass, M. A. Jimenez, D. Andreu, and F. Hudecz. 2003. Conformational study of linear and cyclic peptides corresponding to the 276-284 epitope region of HSV gD-1. Biophys. Chem. 103:51-65.
49. Mikloska, Z., and A. L. Cunningham. 1998. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J. Gen. Virol. 79(Pt. 2):353-361.
50. Mikloska, Z., A. M. Kesson, M. E. Penfold, and A. L. Cunningham. 1996. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma. J. Infect. Dis. 173:7-17.
51. Nalbandian, G., and S. Kovats. 2005. Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol. Res. 31:91-106.
52. + effector T cells during ocular herpes infection. J. Virol. 81:7647-7661.
53. Nesburn, A. B., I. Bettahi, X. Zhang, X. Zhu, W. Chamberlain, R. E. Afifi, S. L. Wechsler, and L. BenMohamed. 2006. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4:178-187.
54. Nesburn, A. B., R. L. Burke, H. Ghiasi, S. M. Slanina, and S. L. Wechsler. 1998. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 252:200-209.
55. Nesburn, A. B., T. V. Ramos, X. Zhu, H. Asgarzadeh, V. Nguyen, and L. BenMohamed. 2005. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23:873-883.
56. Nesburn, A. B., S. Slanina, R. L. Burke, H. Ghiasi, S. Bahri, and S. L. Wechsler. 1998. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J. Virol. 72:7715-7721.
57. intermediate dendritic cells from bone marrow precursors. J. Immunol. 172:1426-1436.
58. Panigada, M., T. Sturniolo, G. Besozzi, M. G. Boccieri, F. Sinigaglia, G. G. Grassi, and F. Grassi. 2002. Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infect. Immun. 70:79-85.
59. Perng, G. C., B. Maguen, L. Jin, K. R. Mott, J. Kurylo, L. BenMohamed, A. Yukht, N. Osorio, A. B. Nesburn, G. Henderson, M. Inman, C. Jones, and S. L. Wechsler. 2002. A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5′ end of the latency-associated transcript produces a protein in infected rabbits. J. Virol. 76:8003-8010.
60. Posavad, C. M., D. M. Koelle, and L. Corey. 1998. Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nat. Med. 4:381-382.
61. Rebbapragada, A., C. Wachihi, C. Pettengell, S. Sunderji, S. Huibner, W. Jaoko, B. Ball, K. Fowke, T. Mazzulli, F. A. Plummer, and R. Kaul. 2007. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. AIDS 21:589-598.
62. Renaudet, O., L. BenMohamed, G. Dasgupta, I. Bettahi, and P. Dumy. 2008. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem 3:737-741.
63. Schmid, D. S., D. R. Brown, R. Nisenbamn, R. L. Burke, D. Alexander, R. Ashley, P. E. Pellett, and W. C. Reeves. 1999. Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. J. Clin. Microbiol. 37:376-379.
64. + T-cell cross-reactivity and heterologous immunity. Immunol. Rev. 211:164-181.
65. Sette, A., and J. Sidney. 1998. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10:478-482.
66. Smith, T. J., L. A. Morrison, and D. A. Leib. 2002. Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants. J. Virol. 76:2054-2061.
67. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363-3373.
68. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
69. Straus, S. E., L. Corey, R. L. Burke, B. Savarese, G. Barnum, P. R. Krause, R. G. Kost, J. L. Meier, R. Sekulovich, S. F. Adair, et al. 1994. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1463.
70. Texier, C., S. Pouvelle, M. Busson, M. Herve, D. Charron, A. Menez, and B. Maillere. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164:3177-3184.
71. Texier, C., S. Pouvelle-Moratille, M. Busson, D. Charron, A. Menez, and B. Maillere. 2001. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31:1837-1846.
72. + T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation. J. Immunol. 172:392-397.
73. + T-cell stimulation by parenchymal cells within sensory ganglia. J. Virol. 79:14843-14851.
74. Villacres, M. C., J. Longmate, C. Auge, and D. J. Diamond. 2004. Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum. Immunol. 65:476-485.
75. Weiss, H. 2004. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 11(Suppl. 1):24A-35A.
76. Welsh, R. M. 2006. Private specificities of heterologous immunity. Curr. Opin. Immunol. 18:331-337.
77. Welsh, R. M., S. K. Kim, M. Cornberg, S. C. Clute, L. K. Selin, and Y. N. Naumov. 2006. The privacy of T cell memory to viruses. Curr. Top. Microbiol. Immunol. 311:117-153.
78. Wilcoxen, S. C., E. Kirkman, K. C. Dowdell, and S. A. Stohlman. 2000. Gender-dependent IL-12 secretion by APC is regulated by IL-10. J. Immunol. 164:6237-6243.
79. Wilson, C. C., B. Palmer, S. Southwood, J. Sidney, Y. Higashimoto, E. Appella, R. Chesnut, A. Sette, and B. D. Livingston. 2001. Identification and antigenicity of broadly cross-re active and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J. Virol. 75:4195-4207.
80. Yamashita, K., and E. Heber-Katz. 1989. Lack of immunodominance in the T cell response to herpes simplex virus glycoprotein D after administration of infectious vims. J. Exp. Med. 170:997-1002.
81. Yasukawa, M., and Y. Kobayashi. 1985. Inhibition of herpes simplex virus replication in vitro by human cytotoxic T cell clones and natural killer cell clones. J. Gen. Virol. 66(Pt. 10):2225-2229.
82. Zarling, J. M., P. A. Moran, L. Brewer, R. Ashley, and L. Corey. 1988. Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine. J. Virol. 62:4481-4485.
83. Zarling, J. M., P. A. Moran, R. L. Burke, C. Pachl, P. W. Berman, and L. A. Lasky. 1986. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J. Immunol. 136:4669-4673.
84. Zarling, J. M., P. A. Moran, L. A. Lasky, and B. Moss. 1986. Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus. J. Virol. 59:506-509.
85. 1 responses and protect against ocular infection. J. Virol. 79:15289-15301.
86. ε-palmitoyl lysine moiety increases uptake and maturation of dendritic cell through a Toll-like receptor 2 pathway and triggers a Th1-dependent protective immunity. Eur. J. Immunol. 34:3102-3114.